Search clinical trials for: ALN-TTR01

Total 257313 results

Linda Van Eldik
Duke Clinical Research Institute; Alzheimer's Association

Completed

A MAD Study of TT301/MW189 in Healthy Volunteers

Healthy Adult Volunteers

United States
Alnylam Pharmaceuticals

Completed

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Amyloidosis

United States, Canada, Argentina, Australia, Bulgaria, Cyprus, Italy, Japan, Malaysia, Netherlands, Portugal, Spain, Sweden, Taiwan, United Kingdom, Germany, France, Korea, Republic of, Brazil, Mexico, Turkey
Alnylam Pharmaceuticals

Completed

Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis

Transthyretin Mediated Amyloidosis (ATTR)

United Kingdom, France, Portugal, Sweden
Alnylam Pharmaceuticals

Completed

Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis

TTR-mediated Amyloidosis

Portugal, Spain, Sweden, Brazil, United States, France, Germany
Alnylam Pharmaceuticals

Approved for marketing

Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

Amyloid Neuropathies | Amyloid Neuropathies, Familial | TTR-mediated Amyloidosis | Amyloidosis, Hereditary | Amyloidosis, Hereditary, Transthyretin-Related | Familial Amyloid Polyneuropathies
Alnylam Pharmaceuticals

Completed

Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant

Amyloidosis, Familial | Transthyretin Amyloidosis

France, Germany, Italy, Portugal, Spain, Sweden, United Kingdom
Alnylam Pharmaceuticals

No longer available

Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy

Transthyretin-mediated Amyloidosis With Cardiomyopathy | ATTR Amyloidosis With Cardiomyopathy

United States
OPKO Health, Inc.

Completed

Effects of TT301 on Cytokine Levels Post Endotoxin Challenge

Traumatic Brain Injury

United States
Alnylam Pharmaceuticals

Completed

Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects

TTR-mediated Amyloidosis

United Kingdom
Alnylam Pharmaceuticals

Active, not recruiting

HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

Transthyretin Amyloidosis | Amyloidosis, Hereditary

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Cyprus, France, Germany, Greece, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, Portugal, Spain, Sweden, Taiwan, United Kingdom
Alnylam Pharmaceuticals

Completed

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

Amyloid Neuropathies | Amyloid Neuropathies, Familial | TTR-mediated Amyloidosis | Amyloidosis, Hereditary | Amyloidosis, Hereditary, Transthyretin-Related | Familial Amyloid Polyneuropathies

United States, Canada, Argentina, Australia, Bulgaria, Cyprus, Italy, Japan, Malaysia, Mexico, Netherlands, Portugal, Spain, Sweden, Germany, France, Brazil, Turkey, Korea, Republic of, Taiwan, United Kingdom
Alnylam Pharmaceuticals

Completed

A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

Polyneuropathy | Hereditary Transthyretin-mediated (ATTRv) Amyloidosis

United States
Alnylam Pharmaceuticals

Active, not recruiting

APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

United States, Australia, Brazil, Bulgaria, France, Italy, Japan, Mexico, Netherlands, Taiwan, United Kingdom, Belgium, Czechia, Denmark, New Zealand, Sweden, Korea, Republic of, Argentina, Chile, Hong Kong, Portugal
Alnylam Pharmaceuticals

Completed

The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

TTR-mediated Amyloidosis

Portugal, Sweden, Brazil, United States, France, Spain, Germany
Alnylam Pharmaceuticals

Completed

A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers

Transthyretin (TTR)-Mediated Amyloidosis

United Kingdom
Turgut İlaçları A.Ş.

Completed

Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects

Healthy Participants

Germany
Alnylam Pharmaceuticals

Completed

Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement

Solid Tumors

United States, Spain
Alnylam Pharmaceuticals

Terminated

A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout

Gout

United Kingdom
Alnylam Pharmaceuticals

Completed

Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment

Solid Tumors

United States, Spain
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD) | Genetic Risk Factor

Korea, Republic of
Alnylam Pharmaceuticals

Terminated

A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis | NASH

United States, Bulgaria, United Kingdom, Belgium, Turkey
Alnylam Pharmaceuticals

Terminated

A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

IgA Nephropathy (IgAN) | Berger Disease | Glomerulonephritis, IgA

Canada, Malaysia, France, Sweden, United Kingdom, Philippines, Singapore, Spain, Taiwan
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Non-Alcoholic Fatty Liver Disease (NAFLD)

Healthy Volunteers | Non-alcoholic Fatty Liver Disease (NAFLD)

United States
Regeneron Pharmaceuticals

Recruiting

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Non-Alcoholic Steatohepatitis (NASH) in Adult Participants at Increased Genetic Risk for This Condition (NASHGEN-2)

Non-alcoholic Steatohepatitis (NASH) | Metabolic Dysfunction Associated Steatohepatitis (MASH)

United States, Korea, Republic of, Puerto Rico, Japan
Alnylam Pharmaceuticals

Terminated

A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

United Kingdom
Alnylam Pharmaceuticals

Completed

The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant

ATTR Amyloidosis | Transthyretin (TTR)-Mediated Amyloidosis | Familial Amyloidotic Polyneuropathy (FAP) | Familial Amyloid Neuropathies

France, Germany, Portugal, United Kingdom, Sweden, Spain
Regeneron Pharmaceuticals

Completed

Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

Paroxysmal Nocturnal Hemoglobinuria

United Kingdom
Regeneron Pharmaceuticals

Recruiting

A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults

Healthy Volunteers

New Zealand
Alnylam Pharmaceuticals

Recruiting

A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

Type 2 Diabetes Mellitus (T2DM)

Canada, United States
Regeneron Pharmaceuticals
Alnylam Pharmaceuticals

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers

Healthy

Belgium
Mario Negri Institute for Pharmacological Research
Alnylam Pharmaceuticals

Withdrawn

Eculizumab to Cemdisiran Switch in aHUS (DANCE)

Atypical Hemolytic Uremic Syndrome

Italy
Regeneron Pharmaceuticals

Recruiting

A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works. (ACCESS-EXT)

Paroxysmal Nocturnal Hemoglobinuria

Taiwan, Korea, Republic of, Turkey, Spain, Thailand, Singapore, Japan, Canada, Malaysia, Poland, Italy, Romania
Alnylam Pharmaceuticals

Active, not recruiting

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1)

Hypertension

United States, United Kingdom, Canada, Puerto Rico, Ukraine
Alnylam Pharmaceuticals

Active, not recruiting

A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 (ILLUMINATE-B)

Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria

United States, France, United Kingdom, Israel, Germany
Alnylam Pharmaceuticals

Recruiting

A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension

Mild to Moderate Hypertension

Japan
Alnylam Pharmaceuticals

Approved for marketing

Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1

Primary Hyperoxaluria

Belgium
Centre Hospitalier Universitaire de Saint Etienne
Ministry of Health, France; Fondation de l'Avenir; Fondation de France; ALN Implants...

Completed

PREPIC 2 : Prevention of Recurrent Pulmonary Embolism by Vena Cava Interruption (PREPIC2)

Venous Thrombosis | Pulmonary Embolism

France
Alnylam Pharmaceuticals

Completed

An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1

Primary Hyperoxaluria | PH1 | RNAi Therapeutic | siRNA | AGT

France, United Kingdom, Netherlands, Israel, Germany
Alnylam Pharmaceuticals

Active, not recruiting

A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (ILLUMINATE-C)

Primary Hyperoxaluria Type 1 | Primary Hyperoxaluria

United States, Italy, France, Lebanon, Belgium, Netherlands, Israel, United Arab Emirates, Australia, Jordan, Turkey
Alnylam Pharmaceuticals

Completed

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus Infections

United States, Australia
Sanofi

Completed

A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

Hemophilia A | Hemophilia B

Bulgaria, Switzerland, United Kingdom, United States, Russian Federation
Alnylam Pharmaceuticals

Recruiting

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) (KARDIA-3)

Hypertension | High Cardiovascular Risk

United States, Canada, Switzerland, United Kingdom
Alnylam Pharmaceuticals

Terminated

A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Antitrypsin Deficiency Liver Disease

United Kingdom
Alnylam Pharmaceuticals

Completed

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 (ILLUMINATE-A)

Primary Hyperoxaluria Type 1 (PH1)

United States, France, United Kingdom, Switzerland, Netherlands, Israel, Germany, United Arab Emirates
Johann Wolfgang Goethe University Hospital

Unknown

Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery (IMAGER)

Glioma | Glioblastoma | Primary Malignant Neoplasm of Nervous System | Metastasis

Germany
Alnylam Pharmaceuticals

Completed

Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1

Primary Hyperoxaluria Type 1 (PH1)

France, United Kingdom, Netherlands, Israel, Germany
The Medicines Company

Completed

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C) (ORION-1)

Diabetes | Familial Hypercholesterolemia | Atherosclerotic Cardiovascular Disease

Canada, Netherlands, United States, United Kingdom, Germany
Alnylam Pharmaceuticals

Terminated

A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection

Hepatitis B | Chronic Hepatitis B | Hepatitis B, Chronic | HBV | Hepatitis B Infection

United Kingdom, New Zealand, Singapore, Korea, Republic of, Australia, Hong Kong
Allergan

Completed

Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia

Presbyopia

United States
Allegro Ophthalmics, LLC

Completed

A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration

Macular Degeneration

Mexico

Search clinical trials for: ALN-TTR01

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations